Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody

Overview

Journal Antibodies (Basel)

Date 2023 Feb 22

PMID 36810514

Authors

Maile Velasquez

Chris OSullivan

Robert Brockett

Amanda Mikels-Vigdal

Igor Mikaelian

Victoria Smith

Andrew E Greenstein

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinase 9 (MMP9), a protease implicated in multiple diseases, is secreted as an inactive zymogen and requires proteolytic removal of the pro-domain for activation. The relative levels and functionality of the pro- and active-MMP9 isoforms in tissues are not characterized. We generated a specific antibody that distinguishes an active form of MMP9, F107-MMP9, from the inactive pro-MMP9 isoform. Using multiple in vitro assays and specimen types, we show that F107-MMP9 expression is localized and disease-specific compared with its more abundant parental pro-form. It is detected around sites of active tissue remodeling, including fistulae of inflammatory bowel and dermal fissures in hidradenitis suppurativa, and is expressed by myeloid cells, including macrophages and neutrophils. Together, our findings provide insights into the distribution and potential role of MMP9 in inflammatory diseases.

Citing Articles

Ten Recommendations for the Next Clinical Trial of the Mediterranean Diet in Inflamm-Aging: Results & Insights from a Scoping Review.

Hanna A, Hartford A, Morassaei S JAR Life. 2024; 13:115-125.

PMID: 39691677 PMC: 11649874. DOI: 10.14283/jarlife.2024.18.

Comparison of Microalgae and Lipid Extracts Effects on UVA-Induced Changes in Human Skin Fibroblasts Proteome.

Atalay Ekiner S, Gegotek A, Domingues P, Domingues M, Skrzydlewska E Mar Drugs. 2024; 22(11).

PMID: 39590789 PMC: 11595653. DOI: 10.3390/md22110509.

elicits subspecies-specific responses in human neutrophils.

Muchova M, Kuehne S, Grant M, Smith P, Nagi M, Chapple I Front Cell Infect Microbiol. 2024; 14:1449539.

PMID: 39450334 PMC: 11499235. DOI: 10.3389/fcimb.2024.1449539.

The Effect of Tissue Inhibitor of Metalloproteinases on Scar Formation after Spinal Cord Injury.

Mishra R, Nielsen B, Trudrung M, Lee S, Bolstad L, Hellenbrand D Cells. 2024; 13(18).

PMID: 39329731 PMC: 11430430. DOI: 10.3390/cells13181547.

Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma.

Nguyen H, Duhon B, Kuo H, Fisher M, Brickey O, Zhang L Neurooncol Adv. 2024; 6(1):vdae058.

PMID: 38887507 PMC: 11181934. DOI: 10.1093/noajnl/vdae058.

References

Stefanidakis M, Ruohtula T, Borregaard N, Gahmberg C, Koivunen E . Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J Immunol. 2004; 172(11):7060-8. DOI: 10.4049/jimmunol.172.11.7060. View

Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J . Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2011; 19(1):318-25. DOI: 10.1245/s10434-011-1686-3. View

Hu J, Van den Steen P, Sang Q, Opdenakker G . Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6(6):480-98. DOI: 10.1038/nrd2308. View

Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C . Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep. 2006; 17(1):217-23. View

Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N . Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem. 1995; 270(12):6691-7. DOI: 10.1074/jbc.270.12.6691. View

Greenfield E . Standard Immunization of Rabbits. Cold Spring Harb Protoc. 2020; 2020(9):100305. DOI: 10.1101/pdb.prot100305. View

Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M . Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. Int J Mol Sci. 2016; 17(6). PMC: 4926402. DOI: 10.3390/ijms17060868. View

Seomun Y, Kim J, Joo C . MMP-14 mediated MMP-9 expression is involved in TGF-beta1-induced keratinocyte migration. J Cell Biochem. 2008; 104(3):934-41. DOI: 10.1002/jcb.21675. View

Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S . Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer. 2009; 40(3-4):91-7. DOI: 10.1007/s12029-009-9091-x. View

10.

Marshall D, Lyman S, McCauley S, Kovalenko M, Spangler R, Liu C . Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One. 2015; 10(5):e0127063. PMC: 4427291. DOI: 10.1371/journal.pone.0127063. View

11.

Vempati P, Karagiannis E, Popel A . A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem. 2007; 282(52):37585-96. DOI: 10.1074/jbc.M611500200. View

12.

Gossage D, Cieslarova B, Ap S, Zheng H, Xin Y, Lal P . Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. Clin Ther. 2017; 40(1):156-165.e5. DOI: 10.1016/j.clinthera.2017.11.011. View

13.

Melani C, Sangaletti S, Barazzetta F, Werb Z, Colombo M . Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007; 67(23):11438-46. PMC: 2646404. DOI: 10.1158/0008-5472.CAN-07-1882. View

14.

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

15.

Vandooren J, Geurts N, Martens E, Van den Steen P, Opdenakker G . Zymography methods for visualizing hydrolytic enzymes. Nat Methods. 2013; 10(3):211-20. DOI: 10.1038/nmeth.2371. View

16.

Fisher K, Fei Q, Laird E, Stock J, Allen M, Sahagan B . Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry. 2002; 41(26):8289-97. DOI: 10.1021/bi012076t. View

17.

Frankowski H, Gu Y, Heo J, Milner R, Del Zoppo G . Use of gel zymography to examine matrix metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures. Methods Mol Biol. 2011; 814:221-33. PMC: 3670093. DOI: 10.1007/978-1-61779-452-0_15. View

18.

Xu D, Suenaga N, Edelmann M, Fridman R, Muschel R, Kessler B . Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics. 2008; 7(11):2215-28. PMC: 2577209. DOI: 10.1074/mcp.M800095-MCP200. View

19.

Van den Steen P, Husson S, Proost P, Van Damme J, Opdenakker G . Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun. 2003; 310(3):889-96. DOI: 10.1016/j.bbrc.2003.09.098. View

20.

Demestre M, Parkin-Smith G, Petzold A, Pullen A . The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol. 2005; 159(1-2):146-54. DOI: 10.1016/j.jneuroim.2004.09.015. View